BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 10979941)

  • 21. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
    Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
    Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.
    Bereshchenko O; Lo Re O; Nikulenkov F; Flamini S; Kotaskova J; Mazza T; Le Pannérer MM; Buschbeck M; Giallongo C; Palumbo G; Li Volti G; Pazienza V; Cervinek L; Riccardi C; Krejci L; Pospisilova S; Stewart AF; Vinciguerra M
    Clin Epigenetics; 2019 Aug; 11(1):121. PubMed ID: 31439048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.
    Boultwood J; Fidler C; Lewis S; MacCarthy A; Sheridan H; Kelly S; Oscier D; Buckle VJ; Wainscoat JS
    Blood; 1993 Nov; 82(9):2611-6. PubMed ID: 8219215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonality in the myelodysplastic syndromes.
    Boultwood J; Wainscoat JS
    Int J Hematol; 2001 Jun; 73(4):411-415. PubMed ID: 11503954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients.
    Ou R; Huang J; Shen H; Liu Z; Zhu Y; Zhong Q; Zheng L; Yao M; She Y; Zhou S; Chen R; Li C; Zhang Q; Liu S
    Leuk Res; 2017 Nov; 62():40-50. PubMed ID: 28982058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.
    Saitoh K; Miura I; Takahashi N; Miura AB
    Blood; 1998 Oct; 92(8):2886-92. PubMed ID: 9763574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.
    Dostalova Merkerova M; Krejcik Z; Votavova H; Belickova M; Vasikova A; Cermak J
    Eur J Hum Genet; 2011 Mar; 19(3):313-9. PubMed ID: 21150891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5q-, twenty-five years later: a synopsis.
    Van den Berghe H; Michaux L
    Cancer Genet Cytogenet; 1997 Mar; 94(1):1-7. PubMed ID: 9078284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
    Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
    Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem cell origin of myelodysplastic syndromes.
    Elias HK; Schinke C; Bhattacharyya S; Will B; Verma A; Steidl U
    Oncogene; 2014 Oct; 33(44):5139-50. PubMed ID: 24336326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
    Bernell P; Jacobsson B; Nordgren A; Hast R
    Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.
    Lane SW; Sykes SM; Al-Shahrour F; Shterental S; Paktinat M; Lo Celso C; Jesneck JL; Ebert BL; Williams DA; Gilliland DG
    Blood; 2010 Apr; 115(17):3489-97. PubMed ID: 20197553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.